Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.
D. Kuter
W. Ghanima
Nichola Cooper
Howard A. Liebman
Lei Zhang
Yu Hu
Yoshitaka Miyakawa
M. Hütter-Krönke
C. Pascual-Izquierdo
E. Lucchini
S. Audia
Matias Cordoba
Heidi Krenz
M. Yao
A. Daak
Medicine